LGVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Longeveron Inc. (LGVN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive trial results for its age-related therapy, the lack of significant trading trends, poor financial performance, and absence of strong technical or proprietary trading signals suggest that it is better to wait for more clarity on its growth trajectory and financial stability.
The MACD is positive and expanding, indicating a bullish signal. However, the RSI is neutral at 60.056, and moving averages are converging, suggesting no strong trend. The stock is trading below the pivot level of 0.587, with key support at 0.511 and resistance at 0.663.
Positive Phase 2b trial results for laromestrocel, showing significant improvement in elderly patients' physical function. Stock price increased by 7% following the announcement.
Revenue dropped significantly by -82.28% YoY in Q3 2025, and the company remains unprofitable with a net income of -$7.22M. No significant insider or hedge fund trading trends. Market sentiment is neutral.
In Q3 2025, revenue dropped to $137,000 (-82.28% YoY). Net income improved but remains negative at -$7.22M (+58.08% YoY). EPS increased to -0.39 (+14.71% YoY). Gross margin improved slightly to 91.24% (+3.41% YoY). Overall, financials indicate weak revenue generation and ongoing losses.
No data available for analyst ratings or price target changes.
